Cycle Pharmaceuticals Made A Proposal To Vanda Pharmaceuticals To Acquire 100% Of Shares For $8/Share, Total Cash Consideration $466M
Portfolio Pulse from Benzinga Newsdesk
Cycle Pharmaceuticals has proposed to acquire 100% of Vanda Pharmaceuticals' shares for $8 per share, totaling $466 million in cash.
June 06, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cycle Pharmaceuticals has made a proposal to acquire Vanda Pharmaceuticals for $8 per share, with a total cash consideration of $466 million. This acquisition offer could lead to a significant increase in VNDA's stock price in the short term as investors react to the potential buyout.
The acquisition proposal at a premium price of $8 per share is likely to drive VNDA's stock price up as investors anticipate the buyout. The total cash consideration of $466 million underscores the seriousness of the offer.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100